Skip to main content
C.Q. Pharmaceutical Holding Co., Ltd. logo

C.Q. Pharmaceutical Holding Co., Ltd. — Investor Relations & Filings

Ticker · 000950 ISIN · CNE0000010K0 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,883 across all filing types
Latest filing 2026-06-01 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000950

About C.Q. Pharmaceutical Holding Co., Ltd.

https://www.cqphar.com

C.Q. Pharmaceutical Holding Co., Ltd. is a comprehensive pharmaceutical enterprise specializing in the distribution, retail, and supply chain management of healthcare products. The company operates an extensive network focused on the wholesale of pharmaceuticals and medical devices, providing integrated logistics and warehousing solutions to healthcare providers and manufacturers. Its core business activities encompass the procurement and distribution of a wide range of prescription drugs, over-the-counter medications, and specialized medical equipment. Through its retail pharmacy operations and third-party logistics services, the company facilitates the efficient delivery of medical supplies. C.Q. Pharmaceutical Holding Co., Ltd. emphasizes technological integration within its supply chain to optimize inventory management and ensure the integrity of healthcare products throughout the distribution lifecycle.

Recent filings

Filing Released Lang Actions
关于回购股份进展的公告
Transaction in Own Shares Classification · 91% confidence The document is a periodic announcement detailing the progress of the company’s share buyback program (number of shares repurchased, prices, compliance with regulations), which falls under the “report of the company buying back its own shares” category. This aligns with the “Transaction in Own Shares” definition (Code: POS).
2026-06-01 Chinese
关于参股子公司签订许可协议的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement disclosing that the company’s investee subsidiary signed a licensing agreement. It is not a full financial report (10-K, IR), an earnings release, nor a proxy, dividend, M&A, or board change. It details a commercial licensing transaction and does not fit any specialized category, so this is best classified as a general regulatory filing announcement (RNS).
2026-05-28 Chinese
北京市竞天公诚律师事务所关于重药控股股份有限公司2025年年度股东会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 82% confidence The document is a legal opinion letter from a law firm witnessing the 2025 Annual General Meeting of shareholders, but its core content is the detailed disclosure of the meeting’s agenda items and the precise voting results (number of shares for/against/abstained and percentages) for each resolution. This aligns with the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA). It is not merely announcing that a report is published (RPA) nor is it the annual report itself, but specifically discloses and certifies the vote outcomes.
2026-05-14 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 24% confidence The document is an announcement of the resolutions and voting results from the company’s 2025 Annual General Meeting (AGM). It lists each agenda item, the number of shares voted for, against, abstained, and declares the outcome (“通过”). This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). It’s not the AGM presentation itself but the formal vote results notice.
2026-05-14 Chinese
关于召开2025年年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a detailed notice to shareholders of the upcoming 2025 Annual General Meeting, outlining meeting date, voting methods, proposal items, registration procedures, and including proxy authorization forms. It is not the AGM presentation itself but is sent to solicit votes and provide meeting information. This matches the Proxy Solicitation & Information Statement category (PSI).
2026-05-11 Chinese
关于回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with regulatory requirements. The text references specific dates, regulatory rules about share repurchases, and the company's board approvals. The document length is short (1128 characters) and it is not a full financial report but an update on share buyback activity. This matches the description of a Transaction in Own Shares (POS) filing, which reports on company share repurchase activities.
2026-05-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.